| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399496 | GILEAD | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
Dec, 2021
(2 years ago) | |
| US7208141 | GILEAD | Inhalable aztreonam aerosol for treatment and prevention of pulmonary bacterial infections |
Dec, 2021
(2 years ago) | |
| US7214364 | GILEAD | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
Dec, 2021
(2 years ago) | |
| US7427633 | GILEAD | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
Dec, 2021
(2 years ago) | |
Cayston is owned by Gilead.
Cayston contains Aztreonam.
Cayston has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Cayston are:
- US8399496
- US7208141
- US7214364
- US7427633
Cayston was authorised for market use on 22 February, 2010.
Cayston is available in for solution;inhalation dosage forms.
Cayston can be used as improve respiratory symptoms in cystic fibrosis in patients with pseudomonas aeruginosa.
The generics of Cayston are possible to be released after 20 December, 2021.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Feb 22, 2017 |
Drugs and Companies using AZTREONAM ingredient
Market Authorisation Date: 22 February, 2010
Treatment: Improve respiratory symptoms in cystic fibrosis in patients with pseudomonas aeruginosa
Dosage: FOR SOLUTION;INHALATION
CAYSTON family patents
